Align Technology closed fiscal year 2025 with a landmark achievement: 22 million patients treated with the Invisalign system worldwide, including over 6.5 million teens and children. The company reported total revenues of $4.0 billion, of which Clear Aligner revenues accounted for $3.2 billion and Systems and Services (primarily iTero scanners) contributed $789.6 million.
The Scale of 22 Million
To put this number in perspective, Align Technology reached its 20 millionth patient milestone in Q1 2025, meaning the company added 2 million patients in approximately nine months. The acceleration reflects both geographic expansion and deepening penetration in existing markets.
The 22 million figure includes treatments across all product tiers — from comprehensive full-arch cases to Invisalign Go (designed for general practitioners performing mild to moderate orthodontic treatment). The inclusion of 6.5 million teens and kids represents a strategic success, as younger demographics were historically resistant to clear aligner adoption and preferred traditional braces.
Manufacturing at Scale
Behind the patient numbers lies an extraordinary manufacturing operation. In 2025, Align manufactured over 2.4 billion individual clear aligners — each custom-designed from a digital treatment plan, 3D-printed as a mold, and thermoformed into the final product. This makes Align one of the world's largest consumers of 3D printing technology, operating massive print farms that produce millions of unique parts daily.
The manufacturing footprint spans facilities in Juarez (Mexico), Ziyang (China), and Wroclaw (Poland). The Wroclaw facility is particularly significant for the European market — it handles production for EMEA cases, reducing shipping times and enabling faster treatment starts for European patients.
Global Practitioner Network
Align reported a record 295,000 active Invisalign-trained practitioners globally in 2025. The "active" designation is significant — it means practitioners who submitted at least one Invisalign case during the trailing twelve months, not simply those who completed training at some point.
The growth of the practitioner network is a key strategic metric. More trained doctors means more patient access, which drives volume. Align invests heavily in clinical education, offering both in-person and digital training programs across dozens of countries. The Invisalign Go program has been particularly effective at expanding the practitioner base beyond orthodontists to include general dentists performing simpler alignment cases.
Financial Highlights
Total 2025 revenues of $4.0 billion represented growth from $3.9 billion in 2024. Clear Aligner revenue of $3.2 billion reflects pricing stability in an increasingly competitive market. The iTero scanner business ($789.6 million) continues to grow as practices invest in digital workflow infrastructure.
Align's financial performance is closely watched by the broader dental industry because it serves as a bellwether for digital dentistry adoption. When Align grows, it signals increasing investment in intraoral scanning, digital treatment planning, and chair-side 3D printing. The company's stock (NASDAQ: ALGN) is one of the most traded dental industry equities.
The iTero Ecosystem
While Invisalign dominates headlines, Align's iTero scanner business is an increasingly important growth driver. iTero scanners serve as the primary digital entry point for orthodontic and restorative workflows. With the 2020 acquisition of exocad, Align now offers an integrated ecosystem from scanning (iTero) through design (exocad) to manufacturing (Invisalign).
The iTero Element 5D scanner, with its built-in NIRI (near-infrared imaging) technology for caries detection, positions the device as more than an impression replacement — it becomes a diagnostic tool that justifies the investment for practices beyond orthodontics.
Competitive Landscape
Despite maintaining market leadership, Align faces intensifying competition from multiple directions. In-office clear aligner solutions powered by chairside 3D printing (using systems from Formlabs, SprintRay, and uLab) enable independent practices to offer competing aligner services with higher margins and faster turnaround.
Regional aligner brands have gained significant market share in Asia (Angel Align in China, K Line Europe) and Latin America. Direct-to-consumer models, while facing regulatory pushback in some markets, continue to expand the addressable patient population.
Align's response has been multi-pronged: emphasizing clinical outcomes data and long-term stability studies, expanding Invisalign Go for simpler cases, deepening iTero-Invisalign integration, and investing in AI-powered treatment planning tools that reduce case complexity for less experienced practitioners.
Relevance for CEE
In Central and Eastern Europe, Invisalign adoption has been growing approximately 25% year-over-year since 2024. Poland, Czech Republic, and Hungary lead regional adoption, driven by increasing consumer demand for aesthetic orthodontics and growing investment in digital dental workflows.
The Wroclaw manufacturing facility gives Align a direct presence in CEE, and the company has been expanding its commercial team across the region. iTero scanners have become standard equipment in CEE orthodontic practices, further embedding Align's ecosystem in regional dental workflows.
For CEE dental professionals, the 22 million patient milestone underscores the maturity and clinical validation of the Invisalign system — an important factor for practices considering investment in clear aligner workflows.
FAQ
How many patients has Invisalign treated? 22 million globally as of end of 2025, including 6.5 million teens and children.
What was Align Technology's revenue in 2025? $4.0 billion total — $3.2 billion from Clear Aligners and $789.6 million from Systems and Services (primarily iTero scanners).
How many doctors are trained on Invisalign? 295,000 active practitioners globally in 2025 — a record number. "Active" means they submitted at least one case in the past 12 months.
Does Align have manufacturing in Europe? Yes, the Wroclaw (Poland) facility handles EMEA production, reducing shipping times for European patients.